Table 1 Baseline characteristics of study participants with peripheral artery disease (N = 90)
From: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
Baseline variable | Trial assignment | ||
|---|---|---|---|
NR+resveratrol | NR alone | Placebo | |
(N = 33) | (N = 28) | (N = 29) | |
Age (years), mean (SD) | 70.73 (8.97) | 73.21 (9.97) | 69.72 (8.29) |
Male, n (%) | 19 (57.58) | 16 (57.14) | 13 (44.83) |
Female, n (%) | 14 (42.42) | 12 (42.86) | 16 (55.17) |
African American, n (%) | 19 (57.58) | 8 (28.57) | 16 (55.17) |
Ankle brachial index, mean (SD) | 0.67 (0.20) | 0.72 (0.18) | 0.64 (0.18) |
Body mass index (kg/m2), mean (SD) | 29.30 (6.66) | 28.65 (3.61) | 30.37 (6.39) |
Current smoker, n (%) | 9 (27.27) | 7 (25.00) | 10 (34.48) |
Former smoker, n (%) | 19 (57.58) | 16 (57.14) | 13 (44.83) |
Myocardial infarction, n (%) | 6 (18.18) | 3 (10.71) | 5 (17.24) |
Heart failure, n (%) | 3 (9.09) | 3 (10.71) | 5 (17.24) |
Stroke, n (%) | 9 (27.27) | 1 (3.57) | 8 (27.59) |
Angina, n (%) | 5 (15.15) | 3 (10.71) | 2 (6.90) |
Pulmonary disease, n (%) | 8 (24.24) | 8 (28.57) | 9 (31.03) |
Diabetes, n (%) | 15 (45.45) | 12 (42.86) | 16 (55.17) |
Intermittent claudication, n (%) | 4 (12.12) | 4 (14.29) | 6 (20.69) |
Atypical leg symptoms other than intermittent claudication, n (%) | 24 (72.73) | 20 (71.43) | 17 (58.62) |
No exertional leg pain, n (%) | 5 (15.15) | 4 (14.29) | 6 (20.69) |
6-min walk distance (meters), mean (SD) | 336.61 (80.75) | 339.18 (103.07) | 325.60 (112.51) |
Total treadmill walking time (min), mean (SD)a | 9.94 (5.26) | 7.29 (4.08) | 7.11 (3.44) |
WIQ distance score, mean (SD) | 40.83 (31.66) | 45.12 (28.20) | 43.47 (24.85) |
WIQ speed score, mean (SD) | 41.40 (25.52) | 47.01 (27.16) | 43.40 (20.50) |
WIQ stair-climbing score, mean (SD) | 57.70 (31.32) | 56.10 (27.18) | 52.30 (30.55) |
